Coverage and predictors of influenza and pertussis vaccination during pregnancy: a whole of population-based study.

Influenza Maternal immunisation Pertussis Vaccine coverage

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
13 Oct 2023
Historique:
received: 18 05 2023
revised: 03 09 2023
accepted: 04 09 2023
pubmed: 24 9 2023
medline: 24 9 2023
entrez: 23 9 2023
Statut: ppublish

Résumé

Respiratory infections including influenza and pertussis are associated with significant morbidity and mortality in mothers and newborns. Vaccination during pregnancy against influenza and pertussis is recommended for all women but data on uptake in Australia is limited. We conducted a retrospective population-based cohort study in Australia's largest state, New South Wales (NSW), using a Perinatal Data Collection (PDC). Data included demographic, pregnancy, and birth details including pertussis and influenza vaccination during pregnancy for all women giving birth between 01 January 2016 and 31 December 2020. We used descriptive statistics to assess uptake of influenza and pertussis vaccination during pregnancy and Poisson loglinear regression to estimate associations between maternal characteristics and vaccine receipt. During 2016-2020, there were 477,776 births (mean maternal age 32.25 years). In 176,255 (36.9%) births the mother received both vaccines; 202,922 (42.5%) influenza and 315,620 (66.1%) pertussis vaccine. From 2016 to 2020, reported coverage increased from 26.7% to 58.7% for influenza and 43.1% to 78.8% for pertussis, respectively. After adjustment, characteristics associated with lower likelihood of receiving influenza and pertussis vaccination included: younger age (<30 years), being born in Australia/New Zealand, from lower socio-economic strata, having previous pregnancies, being later to first antenatal care, utilising the public hospital care model, smoking, having chronic hypertension and BMI > 25 kg/m While reported coverage of both influenza and pertussis vaccine in birthing women in NSW has increased over time, disparities in coverage exist and they highlight areas where evidence-based interventions to improve maternal vaccination could be targeted.

Sections du résumé

BACKGROUND BACKGROUND
Respiratory infections including influenza and pertussis are associated with significant morbidity and mortality in mothers and newborns. Vaccination during pregnancy against influenza and pertussis is recommended for all women but data on uptake in Australia is limited.
METHODS METHODS
We conducted a retrospective population-based cohort study in Australia's largest state, New South Wales (NSW), using a Perinatal Data Collection (PDC). Data included demographic, pregnancy, and birth details including pertussis and influenza vaccination during pregnancy for all women giving birth between 01 January 2016 and 31 December 2020. We used descriptive statistics to assess uptake of influenza and pertussis vaccination during pregnancy and Poisson loglinear regression to estimate associations between maternal characteristics and vaccine receipt.
RESULTS RESULTS
During 2016-2020, there were 477,776 births (mean maternal age 32.25 years). In 176,255 (36.9%) births the mother received both vaccines; 202,922 (42.5%) influenza and 315,620 (66.1%) pertussis vaccine. From 2016 to 2020, reported coverage increased from 26.7% to 58.7% for influenza and 43.1% to 78.8% for pertussis, respectively. After adjustment, characteristics associated with lower likelihood of receiving influenza and pertussis vaccination included: younger age (<30 years), being born in Australia/New Zealand, from lower socio-economic strata, having previous pregnancies, being later to first antenatal care, utilising the public hospital care model, smoking, having chronic hypertension and BMI > 25 kg/m
CONCLUSIONS CONCLUSIONS
While reported coverage of both influenza and pertussis vaccine in birthing women in NSW has increased over time, disparities in coverage exist and they highlight areas where evidence-based interventions to improve maternal vaccination could be targeted.

Identifiants

DOI: 10.1016/j.vaccine.2023.09.008 PMID: 37741762
pubmed: 37741762
pii: S0264-410X(23)01062-9
doi: 10.1016/j.vaccine.2023.09.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

6522-6529

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nusrat Homaira reports a relationship with Merck Sharp & Dohme UK Ltd that includes: consulting or advisory. Nusrat Homaira reports a relationship with Sanofi that includes: consulting or advisory.

Auteurs

Nusrat Homaira (N)

School of Clinical Medicine, Faculty of Medicine, UNSW Sydney, New South Wales, Australia; Respiratory Department, Sydney Children's Hospital Randwick, New South Wales, Australia; James P. Grant School of Public Health, BRAC University, Dhaka, Bangladesh.

Wen-Qiang He (WQ)

Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; School of Population Health, UNSW Sydney, New South Wales, Australia.

Jocelynne McRae (J)

National Centre for Immunisation Research and Surveillance (NCIRS), Sydney Children's Hospital's Network, Westmead, New South Wales, Australia.

Kristine Macartney (K)

Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia; National Centre for Immunisation Research and Surveillance (NCIRS), Sydney Children's Hospital's Network, Westmead, New South Wales, Australia.

Bette Liu (B)

National Centre for Immunisation Research and Surveillance (NCIRS), Sydney Children's Hospital's Network, Westmead, New South Wales, Australia; School of Population Health, UNSW Sydney, New South Wales, Australia. Electronic address: bette.liu@health.nsw.gov.au.

Classifications MeSH